Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Three or more concussions linked with worse brain function in later life

Experiencing three or more concussions is linked with worsened brain function in later life, according to new research.

COVID-19 is a leading cause of death in children and young people in the US

A new study led by researchers at the University of Oxford’s Department of Computer Science has found that, between 2021 and 2022, COVID-19 was a leading cause of death in children and young people in the United States, ranking eighth overall. The results demonstrate that pharmaceutical and public health interventions should continue to be applied to limit the spread of the coronavirus and protect again severe disease in this age group.

New blood test could save lives of heart attack victims

Researchers from the Herring group in Oxford's Department of Physiology, Anatomy and Genetics have developed a blood test that measures stress hormone levels after heart attacks. The test – costing just £10 – could ensure patients receive timely life-saving treatment.

COVID-19 increased public trust in science, new survey shows

A survey of over 2000 British adults has found that public trust in science, particularly genetics, increased significantly during the pandemic. However, those with extremely negative attitudes towards science tend to have high self-belief in their own understanding despite low textbook knowledge.

Major funding for Oxford will help find new cancer treatments

Cancer Research UK and the National Institute for Health and Care Research are investing over £3 million across the next five years into The University of Oxford’s Experimental Cancer Medicine Centre (ECMC). The investment will enable Oxford to expand its portfolio of precision prevention and early detection cancer trials.

Gero Miesenböck awarded 2023 Japan Prize

Professor Gero Miesenböck, The Department of Physiology, Anatomy and Genetics' (DPAG) Waynflete Professor of Physiology and Director of the Centre for Neural Circuits and Behaviour, is one of two scientists to be awarded the 2023 Japan Prize "for their development of methods that use genetically addressable light-sensitive membrane proteins to unravel neural circuit function."

Oxford to lead international consortium to unlock potential of programmable nucleic acid drugs

A consortium led by Matthew Wood, Professor of Neuroscience in the Department of Paediatrics and Director of the Oxford-Harrington Rare Disease Centre, has been awarded £8m of funding from UKRI, LifeArc and the Nucleic Acid Therapy Accelerator (NATA) via the Nucleic Acid Therapies (NAT) Delivery Research Challenge.

Vaccination shown to protect against pregnancy complications from COVID-19 Omicron variant

The global network led by the Oxford Maternal and Perinatal Health Institute (OMPHI) at the University of Oxford has today published, in The Lancet, the results of the ‘2022 INTERCOVID Study’ conducted in 41 hospitals across 18 countries.

Role of lymphatic system in bone healing revealed

It was previously assumed that bones lacked lymphatic vessels, but new research from the MRC Human Immunology Unit at Oxford's MRC Weatherall Institute for Molecular Medicine not only locates them within bone tissue, but demonstrates their role in bone and blood cell regeneration and reveals changes associated with aging.

Molnupiravir doesn't reduce COVID-19 hospitalisations in high-risk vaccinated people

Researchers from the University of Oxford released findings from a clinical trial investigating the effectiveness of the antiviral treatment molnupiravir against COVID-19 – the first treatment tested in the ongoing PANORAMIC trial. In their paper published in The Lancet, they reported that molnupiravir did not reduce hospitalisations or deaths among higher risk, vaccinated adults with COVID-19 in the community.

Load More